Aviado · Research
Longevity Daily
Saturday, October 24, 2026
Listen
Today's Brief
A five-ingredient longevity cocktail that edged out rapamycin in aged mice is today's must-read — and the skeptical framing matters as much as the result. AI is entering the senolytic arena with a precisely designed 9-amino-acid peptide targeting zombie cells, while HHS has released a sweeping new national Alzheimer's strategy signaling serious policy momentum. Our Aviado deep-dive explains how phosphatidylserine works at the membrane level to boost acetylcholine — the neurotransmitter your brain needs most for memory — and why the effects are particularly meaningful after 50.
10 stories3 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Scientists Identify a Brain Gene That Fights Memory Decline With Age
Researchers studying hippocampal neurons have identified PLA2G2F as a key regulator of the brain's compensatory response to age-related damage, helping maintain healthy lipid metabolism in both neurons and supporting microglia cells. Crucially, artificially raising PLA2G2F expression above natural age-related levels produced even greater memory protection — suggesting the gene's ceiling is higher than aging naturally allows. This is early-stage animal research, but it puts lipid dysregulation on the map as an underappreciated driver of cognitive decline and a credible future drug target.
Read more →How Phosphatidylserine Boosts the Brain's Own Memory Neurotransmitter
Your brain's capacity for memory and focus depends on acetylcholine — and phosphatidylserine (PS) may be one of the most direct ways to support its production, by integrating into neuron membranes and enhancing the choline transport systems that feed the synthesis pathway. A year-long clinical study of adults with mild cognitive impairment found significant improvements in memory, arithmetic, and problem-solving for those taking PS versus placebo. At 100–300 mg daily from soy or sunflower sources, the effects are most pronounced in people over 50 or those experiencing early memory changes — making this particularly relevant for proactive cognitive aging strategies.
Read the full Aviado analysis →Supplements & Compounds
Black Cumin Oil May Be a Smarter Sleep Supplement Than Melatonin
A study published in Frontiers in Sleep found that melatonin causes plasma hormone levels to spike sharply and then crash, while black cumin oil extract produced a more gradual, sustained rise — a pharmacokinetic profile that may better mirror the body's natural sleep hormone rhythm. For the millions relying on nightly melatonin, this raises the question of whether that dramatic spike-and-drop is actually ideal for sleep architecture and next-day function. The findings add to growing interest in botanical sleep aids that work with, rather than against, circadian patterns.
Read more →Metformin's Case as a Longevity Drug Is Quietly Getting Stronger
A new review identifies particularly strong mechanistic evidence for metformin across five major hallmarks of aging: deregulated nutrient sensing, mitochondrial dysfunction, impaired autophagy, cellular senescence, and epigenetic alterations. For a drug that costs pennies per dose and carries decades of safety data, the longevity-focused case is becoming harder to dismiss — even before the landmark TAME trial delivers its results. If you follow longevity physicians like Peter Attia, this review synthesizes why so many of them have added metformin to their own protocols.
Read more →A Doctor Says NMN Costs 10x More Than Vitamins — and the Human Evidence Does Not Justify It
A South Korean physician is pushing back against the NMN supplement craze, noting that while David Sinclair's animal studies were striking — old mice fed NMN maintained physical fitness and metabolic function comparable to young mice — the human evidence remains thin, short-term, and largely industry-funded. The doctor's core argument: the premium price is hard to justify when no large, long-term, placebo-controlled human RCT yet exists. A useful reality check for anyone spending serious money on NMN without stress-testing the clinical case.
Read more →Research & Papers
A 5-Ingredient Longevity Cocktail Beat Rapamycin in Mice — But Read the Fine Print
Seragon's SRN-901 — a five-ingredient pill — extended remaining lifespan by 33% in 18-month-old mice and edged out rapamycin alone in a peer-reviewed study, a genuinely striking result from the longevity drug pipeline. Critically, NMN and NR tested as standalone controls showed zero lifespan benefit, which should give NAD+ enthusiasts real pause. This is one company-funded mouse study, and Dr. Jesse Morse's sharp-eyed analysis walks you through exactly what the data can and cannot claim. A must-read for anyone tracking the rapamycin space or wondering whether combination longevity drugs represent the next frontier.
Read more →AI Designs a 9-Amino Acid Peptide to Eliminate Zombie Cells More Safely
Researchers have used AI to engineer a 9-amino-acid peptide that selectively targets senescent cells for elimination, aiming to overcome a critical weakness of existing senolytics — their tendency to affect healthy cells and raise toxicity concerns. The precision of AI-guided design represents a meaningful step beyond chemotherapy-derived compounds like dasatinib that currently dominate the senolytic space. If it holds up in subsequent trials, this approach could open a new class of targeted senolytic therapies with a far cleaner safety profile.
Read more →Lifestyle & Nutrition
ACOG Updated Menopause Guidelines for the First Time in 12 Years — Supplement Claims Take a Hit
The American College of Obstetricians and Gynecologists has issued its first menopause guideline update in over a decade, covering three key symptom categories — and the news is not good for the supplement industry. ACOG explicitly states that available evidence does not support the efficacy or safety of phytoestrogens like soy isoflavones or herbal supplements for treating hot flashes or other menopause symptoms, noting these products bypass FDA review for safety and purity. For women navigating the crowded menopause supplement aisle, these updated clinical guidelines are a critical reference point.
Read more →Industry & Policy
HHS Unveils a Bold New National Strategy to Combat Alzheimer's and Dementia
The U.S. Department of Health and Human Services has released a sweeping new national plan to combat Alzheimer's disease and related dementias — a significant policy move as the condition is projected to affect nearly 14 million Americans by 2060. The plan spans prevention, care delivery transformation, and research acceleration, and arrives as new drug approvals have renewed clinical optimism in the field. For the longevity community, this signals serious government momentum behind brain aging as a public health priority.
Read more →Loyal Scores a Second FDA Acceptance for a Canine Longevity Drug — and the Implications Go Beyond Dogs
Loyal, the biotech using dogs as a fast-track model for longevity drug development, has secured its second FDA Reasonable Expectation of Effectiveness acceptance for a healthy lifespan extension drug in canines. The milestone matters because FDA acceptance signals the agency is willing to evaluate longevity extension as a legitimate drug indication — a precedent that could eventually reshape how human longevity therapeutics are developed and approved. Loyal is quietly building the regulatory framework the entire field will depend on.
Read more →